This study is looking at two different ways to decide when patients need a red blood cell (RBC) transfusion during or after heart surgery. One approach, called the Restrictive Transfusion Strategy, gives transfusions when hemoglobin (a protein in red blood cells) levels are lower. The other, the Liberal Transfusion Strategy, gives transfusions at slightly higher hemoglobin levels. Researchers want to see which strategy leads to better outcomes for patients aged 18 to 65 who are having heart surgery with a heart-lung machine. The study will track serious events like death, heart attack, kidney failure, or stroke for six months after surgery. The study plans to enroll 1440 patients, but its current status is unclear.

Study design

This is an international, multi-center, open-label (meaning you and your doctors will know which treatment you receive) randomized controlled trial. It will compare two common transfusion strategies in up to 1440 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to six months after their cardiac surgery to monitor for specific health events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.